Carrillo ER, Carvajal RR

Language: Spanish
References: 30
Page: 153-159
PDF size: 116.00 Kb.

ABSTRACT

Introduction: Sepsis and septic shock are the main complications in the burned ill patient and are associated with a high morbi-mortality despite the new antibiotics and the organic support. Sepsis is the result of imbalance between coagulation and inflammation in which protein C activated plays a main role. Recombinant Human Protein C Activated (Drotrecogin Alfa Activated) increases survival in severe sepsis. There is few experience in the management of severe sepsis in the burned ill patient with Recombinant Human Protein C Activated. Patients and methods: Two patients with severe burns, severe sepsis and multiple organ dysfunction (MOD) were included. They were followed up with APACHE II, SOFA and oxygenation index (OI) before, during and after the treatment with Recombinant Human Protein C Activated. The dose employed was 24 mg/kg/h for 96 hours as a continuous infusion. Results: The first patient had 60% of total surface area burned and he was infected with Klebsiella pneumoniae and Enterococcus faecalis. The second patient has 40% of total surface area burned and he was infected with Candida spp. Both of them developed severe sepsis with progression to MOD. As the treatment with Drotrecogin alfa activated was initiated the scores of APACHE II and SOFA decreased and the OI increased significantly. The pulmonary dysfunction and infiltrates improved rapidly. There were no bleeding complications, and both patients survived. Conclusion: Recombinant Human Protein C Activated is safe and contributes to revert severe sepsis and MOD in critically ill burned patients. More clinical trials are needed to validate this results.

REFERENCES

1. Appelgren P, Björnhagen, Bragderyd K, Jonson EC, Ransjö. A prospective study of infections in burn patients. Burns 2002;28:39-46.

2. Wurtz R, Karajovic M, Dacumos E, Jovanovic B, Habumadass M. Burns 1995;21:181-184.

3. Edward-Jones V, Greenwood EJ. What’s new in burn microbiology? James Laing Memorial Prize Essay 2000. Burns 2003;29:15-24.

4. Revathi G, Puri J, Jain BK. Bacteriology of burns. Burns 1998;24:347-349.

5. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256.

6. Bauer PR. Microvascular responses to sepsis: clinical significance. Pathophysiology 2002;8:141-148.

7. Huang YS, Yang ZC, Liu XS et al. Serial experimental and clinical studies on the pathogenesis of multiple organ dysfunction syndrome (MODS) in severe burns. Burns 1998;24:706-716.

8. Sheridan RL, Ryan CM, Yin LM et al. Death in the burn unit: sterile multiple organ failure. Burns 1998;24:307-311.

9. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.

10. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.

11. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality patients with septic shock. JAMA 2002;288:862-71.

12. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.

13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.

14. Vincent JL, Moreno R, Takala J, Williatts S et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.

15. Hotchkiss RS, Karl IE. The Pathophysiology and treatment of Sepsis. N Engl J Med 2003;348:138-148.

16. Vincent JL. Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology. Critical Care 2001;5:S1-S5.

17. Carrillo ER, González SJ. Inflamación-endotelio-coagulación en sepsis. Conceptos actuales. Cir Ciruj 2002;70:433-441.

18. Esmon CT. The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness. Critical Care 2001;5:S7-S12.

19. Esmon CT. Inflammation and thrombosis: mutual regulation by protein C. The Immunologist 1998;6:84-89.

20. Esmon CT, Fukudome K, Mather T et al. Inflammation: the protein C pathway. Fibrinolysis Proteolysis 1997;11:143-148.

21. Dettenmeier P, Swindell B, Stroud M et al. Role of activated protein C in the pathophysiology of severe sepsis. American Journal of Critical Care 2003;12:518-526.

22. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23.

23. Taylor FB, Chang A, Esmon CT et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.

24. Hartman DL, Bernard GR, Helterbrand JD et al. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med 1998;24:S1-S77.

25. Grey ST, Tsuchida A, Hau H et al. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994;153:3664-72.

26. Kanji S, Devlin JW, Piekos KA, Racine E. Recombinant human activated protein C, drotrecogin alfa (activated): A novel therapy for severe sepsis. Pharmacotherapy 2001;21:1389-1402.

27. Friedman B, Shaver J, Hickerson W et al. Activated protein C (Drotrecogin alfa); initial experience in critically ill burns. J Burn Care Rehabil 2003;24(suppl 2):S60.

28. Laterre PF, Wittebole X. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis-practical aspects at the bedside and patient identification. Critical Care 2003;7:1186-91.

29. Angus DC, Linde-Zwirble WT, Clermont G et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1-11.

30. Vincent JL, Angus DC, Artigas A et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:834-840.